Compare Bandwidth Inc (BAND) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bandwidth Inc vs Gilead Sciences, Inc. — how do they compare? Bandwidth Inc trades at $52.18 (market cap $1.66B), while Gilead Sciences, Inc. trades at $136.91 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 101.4× Bandwidth Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Bandwidth Inc pays none. Which is the better fit depends on your goals.
| BAND | GILD | |
|---|---|---|
Market Cap | $1.66B | $168.35B |
Sector | Technology | Health |
52-Week High | $78.44 | $155.80 |
52-Week Low | $12.82 | $110.56 |
Enterprise Value | $2.04B | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bandwidth Inc. (BAND) trades at $52.61, down 0.19% today, with a bullish technical trend per moving averages despite overbought RSI signals. Q2 2026 earnings beat expectations with $0.37 EPS, driven by 22% revenue growth and AI-driven communications demand. The company raised its 2026 outlook, highlighting strong enterprise adoption and a record 18.3% adjusted EBITDA margin.
Outlook is positive with 75% analyst buy ratings and a $75.25 consensus price target, but risks include high valuation (EV/EBITDA 34.08) and negative ROE. Earnings growth from AI integration and margin expansion supports upside, though profitability remains thin with a 0.27% net margin projected for 2026.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
